Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route
- PMID: 19635789
- PMCID: PMC2781431
- DOI: 10.1074/jbc.M109.037085
Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route
Abstract
Elevated levels of plasma low density lipoprotein (LDL)-cholesterol, leading to familial hypercholesterolemia, are enhanced by mutations in at least three major genes, the LDL receptor (LDLR), its ligand apolipoprotein B, and the proprotein convertase PCSK9. Single point mutations in PCSK9 are associated with either hyper- or hypocholesterolemia. Accordingly, PCSK9 is an attractive target for treatment of dyslipidemia. PCSK9 binds the epidermal growth factor domain A (EGF-A) of the LDLR and directs it to endosomes/lysosomes for destruction. Although the mechanism by which PCSK9 regulates LDLR degradation is not fully resolved, it seems to involve both intracellular and extracellular pathways. Here, we show that clathrin light chain small interfering RNAs that block intracellular trafficking from the trans-Golgi network to lysosomes rapidly increased LDLR levels within HepG2 cells in a PCSK9-dependent fashion without affecting the ability of exogenous PCSK9 to enhance LDLR degradation. In contrast, blocking the extracellular LDLR endocytosis/degradation pathway by a 4-, 6-, or 24-h incubation of cells with Dynasore or an EGF-AB peptide or by knockdown of endogenous autosomal recessive hypercholesterolemia did not significantly affect LDLR levels. The present data from HepG2 cells and mouse primary hepatocytes favor a model whereby depending on the dose and/or incubation period, endogenous PCSK9 enhances the degradation of the LDLR both extra- and intracellularly. Therefore, targeting either pathway, or both, would be an effective method to reduce PCSK9 activity in the treatment of hypercholesterolemia and coronary heart disease.
Figures






Similar articles
-
The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.Traffic. 2007 Jun;8(6):718-32. doi: 10.1111/j.1600-0854.2007.00562.x. Epub 2007 Apr 25. Traffic. 2007. PMID: 17461796
-
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.J Biol Chem. 2007 Jul 13;282(28):20502-12. doi: 10.1074/jbc.M701634200. Epub 2007 May 10. J Biol Chem. 2007. PMID: 17493938
-
The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.J Biol Chem. 2008 Jan 25;283(4):2363-72. doi: 10.1074/jbc.M708098200. Epub 2007 Nov 26. J Biol Chem. 2008. PMID: 18039658
-
Sorting an LDL receptor with bound PCSK9 to intracellular degradation.Atherosclerosis. 2014 Nov;237(1):76-81. doi: 10.1016/j.atherosclerosis.2014.08.038. Epub 2014 Sep 2. Atherosclerosis. 2014. PMID: 25222343 Review.
-
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21. J Am Coll Cardiol. 2013. PMID: 23973703 Review.
Cited by
-
Angiopoietin-like 4 promotes intracellular degradation of lipoprotein lipase in adipocytes.J Lipid Res. 2016 Sep;57(9):1670-83. doi: 10.1194/jlr.M067363. Epub 2016 Mar 31. J Lipid Res. 2016. PMID: 27034464 Free PMC article.
-
Disruption of endolysosomal trafficking pathways in glioma cells by methuosis-inducing indole-based chalcones.Cell Biol Toxicol. 2017 Jun;33(3):263-282. doi: 10.1007/s10565-016-9369-2. Epub 2016 Nov 7. Cell Biol Toxicol. 2017. PMID: 27822587 Free PMC article.
-
Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.Cardiovasc Res. 2019 Mar 1;115(3):510-518. doi: 10.1093/cvr/cvz003. Cardiovasc Res. 2019. PMID: 30629143 Free PMC article. Review.
-
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond.Curr Atheroscler Rep. 2022 Oct;24(10):821-830. doi: 10.1007/s11883-022-01057-z. Epub 2022 Jul 29. Curr Atheroscler Rep. 2022. PMID: 35904732 Free PMC article. Review.
-
Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance.J Lipid Res. 2018 Aug;59(8):1501-1509. doi: 10.1194/jlr.M086264. Epub 2018 Jun 26. J Lipid Res. 2018. PMID: 29946054 Free PMC article.
References
-
- Lloyd-Jones D., Adams R., Carnethon M., De Simone G., Ferguson T. B., Flegal K., Ford E., Furie K., Go A., Greenlund K., Haase N., Hailpern S., Ho M., Howard V., Kissela B., Kittner S., Lackland D., Lisabeth L., Marelli A., McDermott M., Meigs J., Mozaffarian D., Nichol G., O'Donnell C., Roger V., Rosamond W., Sacco R., Sorlie P., Stafford R., Steinberger J., Thom T., Wasserthiel-Smoller S., Wong N., Wylie-Rosett J., Hong Y. (2009) Circulation 119, e21–e181 - PubMed
-
- Brown M. S., Goldstein J. L. (1986) Science 232, 34–47 - PubMed
-
- Varret M., Abifadel M., Rabès J. P., Boileau C. (2008) Clin. Genet. 73, 1–13 - PubMed
-
- Seidah N. G., Prat A. (2007) J. Mol. Med. 85, 685–696 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous